本年度も新型コロナウイルス感染症への対応に振り回されましたが、自己研鑽の時間を有効活用し、当科のモットーである症例報告を基盤としつつ臨床研究の成果も論文として発信しました。感染制御部、薬剤部との協働もあり、少しずつですが、我々は社会貢献に繋がる学術活動を心がけています。（※ここでいう業績とは発表論文等であり、診療実績や医業収益を指すものではありません）
1. Desquamative interstitial pneumonia with progressive pulmonary fibrosis. Intern Med, in press.
2. Partial pressure of carbon dioxide levels reflect disease severity in idiopathic pleuroparenchymal fibroelastosis. Respir Investig, in press.
3. 肺クリプトコックス症とその他の真菌症. 呼吸器疾患 最新の治療2023-2024 南江堂, 246-249.
4. Impact of nucleic acid amplification test on clinical outcomes in patients with Clostridioides difficile infection. Antibiotics, 12:3,428, 2023.
5. Changes in body weight reflect disease progression in pleuroparenchymal fibroelastosis. Respir Med Res, 83:100980, 2023.
6. A case of pericarditis in a middle-aged woman with COVID-19. Clin Case Rep, 10:12, e06769, 2022.
7. Evaluation of remdesivir for mildly to moderately ill patients with COVID-19: A single-arm, single-center, retrospective study. Medicina, 58:8,1007, 2022.
8. The limited effect of a history of COVID-19 to antibody titers and adverse reactions following BNT162b2 vaccination: a single-center prospective study. J Clin Med, 11:18, 5388, 2022.
9. Basal lung cysts in Birt–Hogg–Dubé syndrome. Intern Med, 61:24, 3755, 2022.
10. Idiopathic pleuroparenchymal fibroelastosis. BMJ Case Rep, 15:7, e251483, 2022.
11. A case of welder’s pneumoconiosis treated with corticosteroid followed by nintedanib. Respir Med Case Rep, 39/101729, 2022.
12. Bilateral pneumothoraces with apical consolidations. Respirol Case Rep, 10:12, e01066, 2022.
13. Pleuroparenchymal fibroelastosis (PPFE). 週刊医学のあゆみ, 283:1,101-105, 2022.
14. Familial pleuroparenchymal fibroelastosis: an entity to be recognized. Respir Med Res, 82:100954, 2022.
15. Clinical impact of amrubicin monotherapy in patients with relapsed small-cell lung cancer: A multicenter retrospective study. Transl Lung Cancer Res. Uda S, et al, 11:9, 1847-1857, 2022.
16. Registry report of initial 50 cases at Fukuoka university lung transplant program. Med. Bull. Fukuoka Univ. Miyahara S, et al, 49:2, 77-84, 2022.
17. Pleuroparenchymal fibroelastosis（二次性も含めて）. 日本臨牀, 80:9, 1480-1484, 2022.
18. 無色透明の気管支肺胞洗浄液を呈した自己免疫性肺胞蛋白症の診断経験. 日肺サーファクタント界面医会誌, 53: 48, 2022.
19. Association of severe COVID-19 outcomes with radiological scoring and cardiomegaly: findings from the COVID-19 inpatients database, Japan. Jpn J Radiol. Tsuchihashi H, et al, 1-10, 2022.
20. Limited efficacy of nintedanib for idiopathic pleuroparenchymal fibroelastosis. Respir Investig, 60: 562-569, 2022.
21. 過敏性肺炎様の画像所見を呈した自己免疫性肺胞蛋白症の1例. 気管支学, 44:4, 295-299, 2022.
22. Association between disease severity according to “MN criteria” and 30-day mortality in patients with Clostridioides difficile infection. J Infect Chemother, 28:6, 757-761, 2022.
23. Lung involvement during the prediagnostic phase of idiopathic pleuroparenchymal fibroelastosis. ERJ Open Res, 8(2):00548-2021, 2022.
